OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy may replace chemo for some throat cancers
Disease control OngoingThis study compares standard treatment (radiation plus chemo drug cisplatin) against two experimental approaches using the immunotherapy drug durvalumab (with or without another drug, tremelimumab) for patients with HPV-positive throat cancer that has spread to lymph nodes but no…
Matched conditions: OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
Could less radiation be just as good for some throat cancers?
Disease control OngoingThis study looks at whether a reduced dose of radiation therapy, combined with the immunotherapy drug nivolumab, can control early-stage HPV-positive throat cancer as well as the standard treatment of radiation plus cisplatin. The trial involves 384 non-smoking participants. The …
Matched conditions: OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:27 UTC
-
New study aims to personalize throat cancer treatment using blood and MRI
Knowledge-focused OngoingThis study looks at whether special blood tests (like tumor DNA) and MRI scans can predict how well chemoradiotherapy works for people with HPV-negative throat cancer. Researchers will follow 30 patients to see if these markers can help doctors choose the best treatment and reduc…
Matched conditions: OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC